ABIONYX Pharma: Financial results for the first half of 2025

ABIONYX Pharma, a company specializing in innovative therapies, has published its half-year results for 2025. Consolidated revenue totaled €2.1 million, generated solely by its subsidiary IRIS Pharma, which is active in ophthalmic contract research. No new studies were entrusted to this subsidiary for the half-year. Research and development expenses decreased to €692,000, but administrative expenses increased to €1.876 million. Net income shows a loss of €2.306 million, an increase compared to 2024.

Despite these losses, cash flow is up slightly to €3.4 million. The company will receive €8.7 million in government support through the France 2030 plan to combat sepsis, enabling ABIONYX to maintain its financial visibility until the second half of 2026.